Daily Sepsis Research Analysis
Analyzed 34 papers and selected 3 impactful papers.
Summary
Three studies stand out today: a multi-omics, genetically anchored analysis identifies plasma ApoE as a biphasic, dose-sensitive modulator of sepsis risk; a secondary analysis of a cluster-randomized NICU trial shows a quality-improvement program reduces acute morbidities including sepsis in extremely preterm infants; and single-cell profiling reveals functional heterogeneity of M-MDSCs that limits classical prognostication and suggests new endotyping strategies.
Research Themes
- Precision biomarkers and causal inference in sepsis risk
- Quality improvement interventions to prevent sepsis-related morbidities
- Immune endotyping and myeloid cell heterogeneity in sepsis
Selected Articles
1. Plasma apolipoprotein E levels and sepsis risk based on multi-center cohorts and multi-omics validation.
Across >500,000 genotyped participants, Mendelian randomization and colocalization supported a causal, U-shaped association between plasma ApoE and sepsis risk, with both low and high levels conferring elevated risk. Findings were replicated in a 291-patient ICU cohort and mirrored mechanistically in murine sepsis models, with lipid-independent effects. ApoE emerges as a mechanistically grounded biomarker and potential therapeutic target for precision modulation.
Impact: Integrating human genetics with clinical and animal validation, this study identifies ApoE as a biphasic modulator of sepsis susceptibility, directly informing risk stratification and therapeutic strategies.
Clinical Implications: Both very low and very high ApoE may signal heightened sepsis risk; measuring ApoE could support early risk stratification. Therapeutically, precision modulation of ApoE rather than simple up/down regulation may be required.
Key Findings
- Genetic colocalization supports a shared causal variant linking ApoE to sepsis (PP.H4 > 0.80).
- ICU cohort shows a U-shaped association: low ApoE (adjusted OR 12.74) and high ApoE (adjusted OR 4.54) increase risk versus mid-range.
- Murine models confirm biphasic effects: both hypo- and hyper-expression worsen inflammation, organ injury, and mortality.
- LDL cholesterol mediates only ~20% of the ApoE-sepsis association, indicating lipid-independent mechanisms.
Methodological Strengths
- Triangulation across Mendelian randomization, colocalization, PheWAS, clinical cohort, and murine models.
- Nonlinear modeling (restricted cubic splines) capturing biphasic risk.
Limitations
- Clinical validation cohort size is modest (n=291) and from ICU settings.
- No interventional trial to test ApoE-targeted modulation.
Future Directions: Prospective trials to test ApoE-guided risk stratification and interventional studies assessing targeted modulation of ApoE pathways.
BACKGROUND: Sepsis remains a leading cause of mortality in critical care, with limited reliable biomarkers that reflect upstream pathophysiology and enable early risk stratification. Apolipoprotein E (ApoE), a lipid transporter with immune-regulatory functions, has shown inconsistent associations with sepsis outcomes. Its causal and clinically actionable role in sepsis risk requires clarification. MATERIALS AND METHODS: We employed a multi-layered strategy integrating Mendelian randomization, colocalization, and phenome-wide association studies across five large proteogenomic cohorts (>500,000 individuals) to identify plasma proteins causally linked to sepsis. ApoE emerged as a top candidate and was validated in a clinical cohort of 291 ICU patients and in murine sepsis models. We assessed the relationship between ApoE levels and sepsis risk using logistic regression, restricted cubic spline models, and survival analyses, and explored underst
2. Cluster-randomized evaluation of neonatal intensive care unit quality improvement interventions in extremely preterm infants: secondary analysis of the INTACT trial.
In a secondary analysis of a cluster-randomized trial across 40 NICUs, a participatory learning-and-action QI program reduced composite acute morbidities among extremely preterm infants, with significant reductions in sepsis and pulmonary hemorrhage in the 22–24 week subgroup and lower overall acute morbidity in 25–27 weeks. No differences were observed in 3-year neurodevelopmental outcomes.
Impact: Demonstrates that structured, participatory QI can reduce acute morbidities including sepsis in extremely preterm infants at scale, supporting implementation in NICUs.
Clinical Implications: NICU teams can adopt participatory learning-and-action QI frameworks to reduce early morbidities such as sepsis in extremely preterm infants, while continuing to monitor long-term neurodevelopment.
Key Findings
- In 25–27 weeks gestation, composite acute morbidity was lower with QI (31.3% vs 40.3%; adjusted OR 0.67; p=0.008).
- In 22–24 weeks gestation, sepsis (adjusted OR 0.44; Holm-adjusted p=0.010) and pulmonary hemorrhage (adjusted OR 0.27; Holm-adjusted p=0.028) were significantly reduced.
- No significant differences in neurodevelopmental outcomes at 3 years after adjustment.
Methodological Strengths
- Cluster-randomized multicenter design with prespecified composite outcomes.
- Multivariable adjustment and Holm correction for multiple comparisons.
Limitations
- Secondary analysis; potential for residual confounding by site-level factors.
- No improvement in 3-year neurodevelopmental outcomes despite acute-phase benefits.
Future Directions: Pragmatic implementation studies to generalize QI frameworks across diverse NICU settings and to test mechanisms linking process improvements to reduced sepsis.
BACKGROUND: The Improvement of Neonatal Intensive Care Unit (NICU) Practices and Team Approach Cluster-randomized Controlled Trial (INTACT) tested a multidisciplinary quality improvement (QI) program but did not show improved survival without neurodevelopmental impairment at 3 years among infants with very low birthweight. However, the program's potential effect on acute-phase outcomes in extremely preterm infants (< 28 weeks of gestation) warrants further evaluation. This secondary analysis aimed to assess the effect of the INTACT study's QI intervention based on participatory learning and action on acute morbidities during the NICU stay and outcomes at 3 years of age. METHODS: We performed a secondary analysis of data from the INTACT trial, a cluster-randomized controlled trial conducted in 40 Japanese NICUs from 2012-2014. Infants were stratified into two gestational age groups (22-24 weeks and 25-27 weeks). The primary outcome was a composite of seven acute morbidities (pulmonary air leak syndrome, pulmonary hemorrhage, sepsis, severe intraventricular hemorrhage, intestinal perforation, necrotizing enterocolitis, or circulatory collapse) between the intervention (QI program) and control groups. Secondary outcomes included chronic morbidities diagnosed before NICU discharge and long-term outcomes at 3 years of age. Multivariable logistic regression and Holm's correction for multiple comparisons were applied.
3. Illustrating the functional heterogeneity of M-MDSCs to predict sepsis outcomes.
Classically defined M-MDSC frequency showed limited prognostic value due to broad functional heterogeneity. Single-cell transcriptomics of purified HLA-DR-defined cells recharacterized M-MDSCs in sepsis, suggesting that transcriptomic endotypes outperform surface-marker counts for outcome prediction.
Impact: Reframes a key myeloid compartment in sepsis by moving beyond surface-marker frequency to functional endotypes, enabling more precise prognostication and immunomodulation strategies.
Clinical Implications: Prognostic stratification based solely on M-MDSC counts is likely insufficient; transcriptomic or functional profiling should be considered for trial enrichment and personalized immunotherapy.
Key Findings
- Classical marker-defined M-MDSC frequency poorly predicts sepsis outcomes due to marked heterogeneity.
- Single-cell RNA sequencing enabled recharacterization of M-MDSC subsets in sepsis.
- Findings support transcriptomic endotyping over surface-marker counts for prognostication.
Methodological Strengths
- Use of single-cell transcriptomics to capture functional heterogeneity.
- Integration of phenotyping with prognostic assessment.
Limitations
- Sample size and multicenter validation are not detailed in the abstract.
- Translational impact requires prospective validation and standardized endotype assays.
Future Directions: Prospective multicenter studies implementing transcriptomic endotyping of myeloid cells to guide immunomodulatory trials in sepsis.
INTRODUCTION: Sepsis remains one of the leading causes of death worldwide. Monocytes play a pivotal role in sepsis due to their dual role in both pro-inflammation and immunosuppression. However, the phenotypic markers and developmental characteristics of immunosuppressive monocytic myeloid-derived suppressor cells (M-MDSCs) in sepsis remain largely unknown. OBJECTIVES: This study aimed to investigate the functional heterogeneity of M-MDSCs in sepsis. METHODS: The frequency of M-MDSCs was assessed for the prognosis of sepsis. Single-cell RNA sequencing was conducted on purified HLA-DR RESULTS: We find that the frequency of M-MDSCs, as defined by classical markers, has limited value in the prognosis of sepsis due to their broad heterogeneity. Based on scRNA-seq analysis, M-MDSCs in sepsis are established as HLA-DR CONCLUSION: This study illuminates the characteristics of M-MDSCs in sepsis, providing a new direction for disease prognosis.